The durability of the immunity is the biggest concern we heard—also even with a booster. When is the next booster? In addition, one option is spacing the booster a little farther—especially for younger cohorts and/or people with prior infections: aka front-loading the supply.
-
-
Replying to @zeynep @gregggonsalves and
Another advantage to an immediate trial is having a better sense of the scale/scope downsides. Some people are going to miss the booster, and require allocation of (limited) resources to track down. So who and when? A trial would help shed light on that.
3 replies 1 retweet 30 likes -
Replying to @zeynep @gregggonsalves and
The problem isn’t trial design. Every one of these options has been written up, designed, proposed. The problem is how many efficacy trials can a society support with finite # of investigators, volunteers, cash and morale, all in the face of multitudes of other important studies.
2 replies 2 retweets 56 likes -
Replying to @k_stephensonMD @zeynep and
In truth, this is the most limiting resource. Ideas are easy, but execution (in this case, of an informative experiment, much less 5 or 10 of them) is the hard(est) problem.
1 reply 0 retweets 16 likes -
Replying to @jallepap @k_stephensonMD and
And suppose a single dose candidate without the need for a (super) cold chain emerges, less expensive and easier to produce? As
@k_stephensonMD suggests the trade-offs are larger here: what do we do with limited time, resources and money? 1/1 reply 0 retweets 12 likes -
Replying to @gregggonsalves @jallepap and
Important thing here is not to ask is this a good idea, but in the words of one of the smartest people I know (
@ADPaltiel), but to ask compared to what? Choices are trade-offs. Have to pull out and look at the entire landscape of vaccine development. End/1 reply 1 retweet 23 likes -
Replying to @gregggonsalves @jallepap and
Resources are limited to the degree there is no push for more resources. We live in very very wealthy countries, and if we start “with resources limited” and stop there we don’t get the resources. It’s exactly the reason to push for more.
2 replies 2 retweets 30 likes -
Replying to @zeynep @ElissaBeth and
If the resource being discussed is people with the necessary skills to handle large scale human trials, what exactly does "getting more" look like?
1 reply 0 retweets 1 like -
Replying to @zero132132 @zeynep and
The resources simply aren’t an issue. If we want to run the trials, we can. It’s an issue of will. In US, decision makers will not benefit from moving to a single dose. They’ll all be vaccinated. So we are witnessing a lack of will and breakdown of global responsibility.
2 replies 2 retweets 8 likes -
Replying to @michaelmina_lab @zero132132 and
I'm just a little sensitive about 'resources aren't an issue' - as I sit in my office updating ipads for the next vaccine trial, kids at home on holiday, wondering how many more days like this can I give. And I'm not the only one of these 'resources' who feel this way.
5 replies 3 retweets 37 likes
What would help? More people? How could we get there? We can push for the money, and how could that money be translated into personnel? Also for what it’s worth, country’s like my home country, Turkey, are running trials and have a lot of qualified personnel.
-
-
Replying to @zeynep @k_stephensonMD and
There are multiple bottlenecks, and the task is to figure out how to best get through them. Given the history of how this works, it’s no small threat that once we get most privileged ~billion vaccinated, the pressure goes away. So asking for the right things is important.
1 reply 4 retweets 13 likes -
Replying to @zeynep @michaelmina_lab and
This is a really good point, and I completely agree. The US has prioritized individual-benefit trials. Hopefully
@JoeBiden and team will see differently. Your advocacy can only help, and I'm thankful for that. And there are many brilliant physician-scientists abroad. 100% agree.1 reply 0 retweets 4 likes - Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.